<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595281</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A01511-46</org_study_id>
    <nct_id>NCT02595281</nct_id>
  </id_info>
  <brief_title>HE4 as a Relapse Biomarker in Ovarian Cancers</brief_title>
  <acronym>PRONOV4IR</acronym>
  <official_title>Determination of the Interest of HE4 as a Relapse Biomarker in Ovarian Cancers Stages IIIb, IIIc and IV After Neo-adjuvant Chemotherapy and Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HE4 is a more sensitive marker than CA-125 in patients with ovarian cancers. The interest of&#xD;
      serum HE4 before surgery has been demonstrated to predict overall survival and its interest&#xD;
      has also been shown in combination with CA-125 (ROMA algorithm) to identify high risk&#xD;
      patients. To date, no study shows clearly the predictive potential of serum HE4 as an early&#xD;
      relapse biomarker in ovarian cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the predictive and prognostic value of HE4 marker</measure>
    <time_frame>24 months</time_frame>
    <description>Serum concentration of HE4 (pMol) will be analysed at each visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the evolution of HE4 and CA-125 serum concentration</measure>
    <time_frame>24 months</time_frame>
    <description>Serum concentration of HE4 and CA-125 (pMol) will be analysed and compared at the time of diagnosis, at each neoadjuvant chemotherapy cycle, before the surgery, and at each chemotherapy cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the progression-free survival at 18 months</measure>
    <time_frame>24 months</time_frame>
    <description>HE4 and CA125 will be compared with the rate of progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of surgery</measure>
    <time_frame>24 months</time_frame>
    <description>HE4 and CA125 will be compared with completeness of cancer resection score (CCR score).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental arm</intervention_name>
    <description>Serum samples are collected:&#xD;
at each neoadjuvant chemotherapy cycle&#xD;
before surgery&#xD;
at each adjuvant chemotherapy cycle&#xD;
at each injection of bevacizumab as maintenance therapy&#xD;
stop at the progression or after 24 months post chemotherapy</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ovarian adenocarcinoma stage IIIa, IIIb or IV pleural, cytologically or histologically&#xD;
             proven&#xD;
&#xD;
          -  Patient scheduled to undergo neoadjuvant chemotherapy based on platinum followed by&#xD;
             surgery and adjuvant chemotherapy&#xD;
&#xD;
          -  Age ≥ 18 years .&#xD;
&#xD;
          -  Performance status ECOG &gt; or = 2&#xD;
&#xD;
          -  Adequate haemoglobin rate ≥ 10 g/dL&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Patient's legal capacity to consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous treatment with platinum for ovarian carcinoma&#xD;
&#xD;
          -  Patient with visceral metastases&#xD;
&#xD;
          -  Contraindication for blood test&#xD;
&#xD;
          -  Contraindication for surgery&#xD;
&#xD;
          -  Contraindication for bevacizumab treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline Gavoille, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BENGRINE-LEVEVRE Leïla</name>
      <address>
        <city>Dijon</city>
        <state>Centre Georges François Leclerc</state>
        <zip>21 079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZEMAR Marc</name>
      <address>
        <city>Strasbourg</city>
        <state>Centre Paul Strauss</state>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LONGO Raphaelle</name>
      <address>
        <city>Metz</city>
        <state>CHU Metz Thionville</state>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KURTZ Jean-Emmanuel</name>
      <address>
        <city>Strasbourg</city>
        <state>Hôpital Civil</state>
        <zip>67 091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KALBACHER Elsa</name>
      <address>
        <city>Besançon</city>
        <state>Hôpital Jean Minjoz</state>
        <zip>25 030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GAVOILLE Céline</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Institut De Cancérologie De Lorraine</state>
        <zip>54 519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAVOYE Aude-Marie</name>
      <address>
        <city>Reims</city>
        <state>Institut Jean Godinot</state>
        <zip>51 056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Carcinoma</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>ROMA</keyword>
  <keyword>Ca125</keyword>
  <keyword>HE4</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

